Dr. Zamarin on the Role of Pembrolizumab in Endometrial Cancer

Dmitriy Zamarin, MD, PhD
Published: Monday, Nov 06, 2017



Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of pembrolizumab (Keytruda) for patients with endometrial cancer.

Ovarian cancer is not the only cancer that we treat with immunotherapy, explains Zamarin. Immunotherapy has been shown to be effective in endometrial cancer. Pembrolizumab has been FDA approved for microsatellite instability-high (MSI-H) endometrial cancers or for any MSI-H tumor. There is preliminary evidence that was presented, demonstrating that even in a non-MSI-H population, these immune checkpoint inhibitors can work.

Preliminary data presented at ASCO demonstrated the combination of an immune checkpoint inhibitor with a targeted agent. According to Zamarin, when lenvatinib (Lenvima) was combined with pembrolizumab, the response rate was 50%.


Dmitriy Zamarin, MD, PhD, a medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of pembrolizumab (Keytruda) for patients with endometrial cancer.

Ovarian cancer is not the only cancer that we treat with immunotherapy, explains Zamarin. Immunotherapy has been shown to be effective in endometrial cancer. Pembrolizumab has been FDA approved for microsatellite instability-high (MSI-H) endometrial cancers or for any MSI-H tumor. There is preliminary evidence that was presented, demonstrating that even in a non-MSI-H population, these immune checkpoint inhibitors can work.

Preliminary data presented at ASCO demonstrated the combination of an immune checkpoint inhibitor with a targeted agent. According to Zamarin, when lenvatinib (Lenvima) was combined with pembrolizumab, the response rate was 50%.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Redefining Ovarian Cancer Treatment Paradigms by Maximizing Therapeutic Outcomes with PARP InhibitorsSep 29, 20182.0
Community Practice Connections™: Bridging the Gaps Around Oncology Biosimilars: Assessing the Potential Impact of Emerging Agents to PracticeSep 29, 20181.5
Publication Bottom Border
Border Publication
x